-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: BIOtechNOW Editor
Playing Detective With Checkpoint Therapies
Three words are on the lips of everyone following new developments in cancer therapies: checkpoint inhibitor drugs. Simply put, investigators believe they have figured out a way to dismantle the mechanism used by cancer cells to stay hidden from T-cells, a type of specialized immune cell. CTLA-4 is a protein on the surface of T-cells that acts as an “off” switch for the sleuthing T-cells. It signals them to remain in a resting state, kind of like Read More >
NCATS SBIR Announces Funding For Biotechs and Small Business Technology Development
The NIH National Center for Advancing Translational Sciences (NCATS) is seeking qualified applicants for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. NCATS, which offers $17.6 million annually through these programs, has issued a call for applications for two funding opportunities: Contract funding to support small businesses and venture-backed technology development, due Nov. 5, 2014. Investigator-initiated grant funding,due Dec. 5, 2014. NCATS’ SBIR and STTR programs are engines of innovation Read More >
ALS Ice Bucket Challenge Brings Attention to the Need For Private Funding
The ALS Ice Bucket Challenge – the social media phenomenon in which people post videos of themselves dumping buckets of water on their heads – has swept through social media like wildfire as part of an effort to raise both awareness and funding for ALS research. It’s pretty safe to say that it’s working. As of Thursday morning, the ALS Association had received $41.8 million from existing donors and more than 739,000 new donors over Read More >
Jim Greenwood Talks 21st Century Cures with Chairman Fred Upton
Recently, BIO CEO and President Jim Greenwood sat down with House Energy and Commerce Chairman Fred Upton (R-MI) to talk about the Committee’s 21st Century Cures initiative, which seeks to “determine what steps we can take to ensure we are taking full advantage of the advances this country has made in science” to speed and improve drug discovery, development and delivery. This is a bipartisan effort Chairman Upton and the committee are undertaking with the Read More >
Is Regulatory Transformation for Alzheimer’s Therapies Needed?
BIO 2014′s session titled ” Regulatory Transformation: As Alzheimer’s Disease Science, Research and Advocacy Move Toward Earlier Detection and Intervention, How Will Researchers Adapt to this Evolution?” discussed progress and challenges facing researchers and the collaborative efforts between the Food and Drug Administration (FDA) and patient advocacy groups to help them find a cure. The discussion centered on recent FDA Draft Guidance for Early Stage Alzheimer’s Disease Drug Development which allows for an accelerated approval Read More >
